LCZ696(Sacubitril + Valsartan)

Tlhaloso e Khutšoanyane:

Lebitso la API Pontsho Tlhaloso US DMF EU DMF CEP
LCZ696(Sacubitril + Valsartan) Ho hloleha ha pelo Ka Ntlong    


Lintlha tsa Sehlahisoa

Li-tag tsa Sehlahisoa

TLHAKISO SEHLAHISO

Tlhaloso

LCZ696 (Sacubitril/Valsartan), e nang le Valsartan (an ARB) le Sacubitril (AHU377) ka karolelano ea 1: 1 molar, ke ea pele-pele, ka molomo bioavailable, le dual-acting angiotensin receptor-neprilysin (ARN) inhibitor bakeng sa hypertension. le ho hloleha ha pelo [1][2][3].LCZ696 e matlafatsa lefu la pelo ea lefu la tsoekere ka ho thibela ho ruruha, khatello ea oxidative le apoptosis.

 

Ka morao

LCZ696 ke ea pele sehlopheng sa ARNi (angiotensin receptor neprilysin inhibitor) e nang le likarolo tsa anionic tsa AR valsartan le neprilysin inhibitor prodrug AHU377 (1: 1 ratio) bakeng sa ho hloleha ha pelo le khatello ea mali.

Li-angiotensin receptors ke li-receptor tsa G-protein tse kopantsoeng.Li kopanya methapo ea pelo le litlamorao tse ling tsa angiotensin II, e leng bioactive peptide ea sistimi ea renin-angiotensin.Neprilysin ke endopeptidase e sa nke lehlakore e senyang li-peptide tsa vasoactive tse kang li-peptide tsa natriuretic.Ho thibela neprilysin ho eketsa mahloriso a li-peptide tsa natriuretic tse tlatselitseng ts'ireletsong ea pelo, methapo le renal.[1]

Ho likhoto tsa Sprague-Dawley, tsamaiso ea molomo ea LCZ696 e lebisitse ho phahama ho itšetlehileng ka tekanyo ea immunoreactivity ea atrial natriuretic peptide e bakoang ke thibelo ea neprilysin.Likhotong tsa hypertensive tse peli tsa transgenic, LCZ696 e bakile ho fokotseha ho itšetlehileng ka tekanyo le ho tsitsitseng ho bolelang khatello ea mali.Barupeluoa ba phetseng hantle, thuto e laoloang ka mokhoa o sa reroang, e sa boneng habeli, e laoloang ke placebo e netefalitse hore LCZ696 e fane ka thibelo ea neprilysin ka nako e le 'ngoe le ho thibela li-receptor tsa AT1.LCZ696 e ne e bolokehile ebile e mamelloa hantle ho batho.[2] [3]

Litšupiso:
McMurray JJ, Packer M, Desai AS et al.Angiotensin-neprilysin inhibition khahlano le enalapril ka ho hloleha ha pelo.N Engl J Med.2014 Sep 11;371(11):993-1004.
Gu J, Noe A, Chandra P, Al-Fayoumi S et al.Pharmacokinetics le pharmacodynamics ea LCZ696, buka e ncha e sebetsang ka bobeli ea angiotensin receptor-neprilysin inhibitor (ARNi).J Clin Pharmacol.2010 Apr;50(4):401-14.
Langenickel TH, Dole WP.Angiotensin receptor-neprilysin inhibition le LCZ696: mokhoa o mocha oa phekolo ea lefu la pelo, Drug Discov Today: Ther Strategies (2014),

 

Polokelo

Phofo

-20°C

3 lilemo
 

4°C

lilemo tse 2
Ka solvent

-80°C

Likhoeli tse 6
 

-20°C

1 khoeli

Sebopeho sa lik'hemik'hale

LCZ696(Sacubitril + Valsartan)

TSAMAISO KHABANE

Quality management1

Tlhahiso18Merero ea Tlhahlobo ea Boleng e amohetsoeng4, le6merero e tlas'a tumello.

Quality management2

Sistimi e tsoetseng pele ea boleng ba machaba e thehile motheo o tiileng oa thekiso.

Quality management3

Tlhokomelo ea boleng e tsamaisana le potoloho eohle ea bophelo ba sehlahisoa ho netefatsa boleng le phello ea kalafo.

Quality management4

Sehlopha sa Litaba tsa Taolo ea Setsebi se tšehetsa litlhoko tsa boleng nakong ea kopo le ngoliso.

TS'ELISO TS'OANELO

cpf5
cpf6

Korea Countec Bottled Packaging Line

cpf7
cpf8

Taiwan CVC Bottled Packaging Line

cpf9
cpf10

Italy CAM Board Packaging Line

cpf11

Mochini oa Sejeremane oa Fette Compacting

cpf12

Japan Viswill Tablet Detector

cpf14-1

Kamore ea ho laola ea DCS

MOTHOANA

Tšebelisano ea machaba
International cooperation
Tšebelisano 'moho ka lapeng
Domestic cooperation

  • E fetileng:
  • E 'ngoe:

  • Ngola molaetsa wa hao mona mme o re romele wona

    Lihlopha tsa lihlahisoa